Should we still be using bolus 5-FU prior to infusional regimens in gastrointestinal cancers? A practical review

5-fluorouracil (5-FU), a pyrimidine analogue with antimetabolite activity, is one of the most widely used drugs in Oncology and many different regimens have been described regarding its use. Nowadays, the modified de Gramont is the most popular schedule of 5-FU to treat gastrointestinal cancers and...

Full description

Saved in:
Bibliographic Details
Published inInternational cancer conference journal Vol. 11; no. 1; pp. 2 - 5
Main Authors Amorim, Larissa Costa, Peixoto, Renata D’Alpino
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.01.2022
Springer Nature B.V
Subjects
5-Fluorouracil
Clinical outcomes
Clinical trials
Colorectal cancer
Drug dosages
Enzymes
Gastrointestinal cancer
Irinotecan
Medicine
Medicine & Public Health
Metastasis
Monoclonal antibodies
Oncology
Oxaliplatin
Pancreatic cancer
Response rates
Review
Review Article
Surgical Oncology
Toxicity
Bolus 5-fluorouracil
Leucovorin
Infusional 5-FU
Pancreatic cancer
Colorectal cancer
Online AccessGet full text

Cover

More Information
Summary:5-fluorouracil (5-FU), a pyrimidine analogue with antimetabolite activity, is one of the most widely used drugs in Oncology and many different regimens have been described regarding its use. Nowadays, the modified de Gramont is the most popular schedule of 5-FU to treat gastrointestinal cancers and may be given either alone or combined with irinotecan, oxaliplatin and monoclonal antibodies. The true clinical value of bolus 5-FU right before infusional regimens remains to be determined since no randomized trials have addressed this issue. This manuscript aims to review the history of 5-FU, its mechanism of action and the data exploring the role of bolus 5-FU.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2192-3183
2192-3183
DOI:10.1007/s13691-021-00526-7